N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics

Clinical Schizophrenia and Related Psychoses

Volumn 7, Issue 2, 2013, Pages

  Fetter, Jeffrey Charles ^a   Brunette, Mary ^b   Green, Alan I ^b  

^a New Hampshire Dartmouth Psychiatric Research Center   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic; Cardiometabolic risk; Metabolic syndrome; Omega 3 fatty acid; Schizophrenia; Triglyceride

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OMEGA 3 ACID ETHYL ESTER; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; MALE; OPEN STUDY; PILOT STUDY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; C-REACTIVE PROTEIN; CHOLESTEROL; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN; MALE; MENTAL DISORDERS; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 84880673374     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.FEBR.012513     Document Type: Article

References (55)

1. Newcomer J. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry 2006;67(Suppl 9):36-42.
2. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease 2006. Retrieved February 11, 2010 from http://www.cdc.gov/PCD/issues/2006/apr/pdf/05-0180.pdf.
3. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
4. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157(6):975-981.
5. Henderson DC, Nguyen DD, Copeland PM, Hayden MA, Borba CP, Louie PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66(9):1116-1121.
6. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008;101(1-3):273-286.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-1223.
8. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60(6):358-363.
9. Allison DB, Mentore JL, Heo M, Chandler L, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-1695.
10. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32(2):289-297.
11. Zhang ZJ, Yaho ZJ, Liu W, Fang Q, Reynolds GP. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62.
12. Newcomer JW, Haupt DW, Fucetola R, Melson AD, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59(4):337-345.
13. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62(1):19-28.
14. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006;26:504-507.
15. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63(5):856-865.
16. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2003;65(5):686-689.
17. Brunzell JD. Clinical practice: hypertriglyceridemia. N Engl J Med 2007;357(10):1009-1017.
18. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139(10):802-809.
19. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 2006;16(Suppl 3):S149-155.
20. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and diabetes. J Clin Psychiatry 2004;65(2):267-272.
21. Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L. Statins are effective in treating dyslipidemia among psychiatric patients using second generation antipsychotic agents. J Psychopharmacol 2008;22(1):33-38.
22. Landry P, Dimitri E, Tessier S, Legare N. Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. J Clin Psychopharmacol 2008;28(3):348-349.
23. Wing RR, Tate D, Gorin A, Hollie AR, Fava JL. A self-regulation program for maintenance of weight loss. NEJM 2006;355(15):1563-1571.
24. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-2095.
25. ™ package insert. Retrieved March 31, 2008 from http://www.lovaza.com/pdfs/LOVAZA-Prescribing- Info.pdf.
26. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, et al.; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-1367.
27. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 2007;6:21.
28. Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebocontrolled trial. Schizophr Res 2006;84(1):112-120.
29. Canniato RN, Alvarenga ME, Garcia-Alcaraz MA. Effect of omega-3 fatty acids on the lipid profile of patients taking clozapine. Aust N Z J Psychiatry 2006;40(8):691-669.
30. Skourliakou M, Giannopoulou I, Kostara C, Hannon JC. Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine. Nutrition 2009;25(7-8):729-735.
31. Wu MK, Wang CK, Bai YM, Huang CY, Lee SD. Outcomes of obese, clozapinetreated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv 2007;58(4):544-550.
32. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, et al. Attenuation of antipsychoticinduced weight gain with early behavioral intervention in drug-naive first episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006;67(8):1253-1260.
33. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008;165(3):352-358.
34. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA 2008;299(2):185-193.
35. Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93(1-3):99-108.
36. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006;163(12):2072-2079.
37. Cates ME, Feldman JM, Boggs AA, Woolley TW, Whaley NP. Efficacy of addon topiramate therapy in psychiatric patients with weight gain. Ann Pharmacother 2008;42(4):505-510.
38. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res 2006;82(1):115-117.
39. Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005;28(4):169-175.
40. Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry 2005;162(5):954-962.
41. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007;115(2):101-105.
42. Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al. Orlistat in clozapine-or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69(5):706-711.
43. Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr Res 2008;101(1-3):273-286.
44. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychiatry 2003;23(6):595-600.
45. Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27(12):1930-1941.
46. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holiday RM, Sweetnam PM, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2(8666):757-761.
47. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al.; GISSI-Prevenzione Investigators. Early protection against sudden death by N-3 polyunsaturated fatty acids after myocardial infacrtion: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105(16):1897- 1903.
48. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al.; Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-1098.
49. Podolin DA, Gayles EC, Wei Y, Thresher JS, Pagliassotti MJ. Menhaden oil prevents but does not reverse sucrose-induced insulin resistance in rats. Am J Physio 1998;274:840-848.
50. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al. N-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 2009;52(5):941-951.
51. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long chain omega-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry 2010;67:146-154.
52. Look AHEAD Researchers. Long term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with Type 2 diabetes mellitus: four year results of the Look AHEAD trial. Arch Int Med 2010;170:1566-1575.
53. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, et al.; GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Int Med 2008;10:2194-2204.
54. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 2002;346:393-403.
55. De Hert M, Kalnicka D, Van Winkel R, Wampers M, Hanssens L, Van Eyck D, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2006;67:1889-1896.